The expression levels of SPARC in clinical samples were evaluated in a cDNA array assay which included normal tissues and tissues from grade I to IV head and neck cancer patients, including carcinoma of tonsil, pharynx, oropharynx, etc. Our results revealed that mRNA levels of SPARC in normal tissues are significantly lower than that in cancer. The gene discussed is SPARC; the disease is cancer.